Peer review reports
From: A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease
Original Submission |
11 May 2022 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
11 Jul 2022 |
Reviewed |
Reviewer Report
|
12 Jul 2022 |
Reviewed |
Reviewer Report
|
11 Aug 2022 |
Author responded |
Author comments - Deirdre Mladsi
|
Resubmission - Version 3 |
11 Aug 2022 |
Submitted |
Manuscript version 3
|
26 Aug 2022 |
Reviewed |
Reviewer Report
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
Publishing |
12 Sep 2022 |
Editorially accepted |
|
18 Oct 2022 |
Article published |
10.1186/s12882-022-02956-8
|
Learn about peer review